Stage phase II clinical trials with continuous outcomes

Journal of Biopharmaceutical Statistics

Volumn 22, Issue 4, 2012, Pages 836-852

  Wason, James M S ^a   Mander, Adrian P ^a  

^a MRC BIOSTATISTICS UNIT   (United Kingdom)

Author keywords

Minimax design; Optimal design; Two stage designs

Indexed keywords

ARTICLE; CLUSTER ANALYSIS; CONTINUOUS TREATMENT RESPONSE; MATHEMATICAL ANALYSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SAMPLE SIZE; STUDY DESIGN; TREATMENT OUTCOME; TWO STAGE PHASE 2 CLINICAL TRIAL; ALGORITHM; HUMAN; METHODOLOGY; PROBABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL ANALYSIS; STATISTICS;

ALGORITHMS; CLINICAL TRIALS, PHASE II AS TOPIC; DATA INTERPRETATION, STATISTICAL; HUMANS; PROBABILITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SAMPLE SIZE;

EID: 84863456029     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543406.2010.528104     Document Type: Article

References (14)

1. Eales, J. D., Jennison, C. (1995). Optimal two-sided group sequential tests. Sequential Analysis 14:273-286.
2. Eisenhauer, E., Therasse, P., Bogaerts, J., et al. (2009). New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer 45:228-247.
3. Farewell, V., Tom, B., Royston, P. (2004). The impact of dichotomization on the efficiency of testing for an interaction effect in exponential family models. Journal of the American Statistical Association 99:822-831. (Pubitemid 39332864)
4. Jennison, C., Turnbull, B. (2000). Group Sequential Methods with Applications to Clinical Trials. Boca Raton, FL: Chapman and Hall.
5. Jones, C., Holmgren, E. (2007). An adaptive simon two-stage designs for phase 2 studies of targeted therapies. Contemporary Clinical Trials 28:654-661. (Pubitemid 47212846)
6. Jung, S., Lee, T., Kim, K., George, S. (2004). Admissible two-stage designs for Phase II cancer clinical trials. Statistics in Medicine 23:561-569. (Pubitemid 38208184)
7. Karrison, T., Maitland, M., Stadler, W., Ratain, M. (2007). Design of Phase II cancer trials using a continuous endpoint of change in tumour size: Application to a study of sorafenib and erlotinib in non-small-cell lung cancer. JNCI 99:1455-1461.
8. Lee, J., Feng, L. (2005). Randomized Phase II designs in cancer clinical trials: current status and future directions. Journal of Clinical Oncology 23:4450-4457. (Pubitemid 46209969)
9. Li, G., Shih, W., Xie, T., Lu, J. (2002). A sample size adjustment procedure for clinical trials based on conditional power. Biostatistics 3:277-287.
10. Posch, M., Bauer, P. (1999). Adaptive two stage designs and the conditional error function. Biometrical Journal 6:689-696.
11. Proscan, M., Hunsberger, S. (1995). Designed extension of studies based on conditional power. Biometrics 51:1315-1324. (Pubitemid 26030176)
12. Shuster, J. (2002). Optimal two-stage designs for single-arm Phase II cancer trials. Journal of Biopharmaceutical Statistics 22:39-51. (Pubitemid 34786911)
13. Simon, R. (1989). Optimal two-stage designs for Phase II clinical trials. Controlled Clinical Trials 10:1-10. (Pubitemid 19099520)
14. Whitehead, J., Valdes-Marquez, E., Lissmats, A. (2009). A simple two-stage design for quantitative responses with application to a study in diabetic neuropathic pain. Pharmaceutical Statistics 8:125-135.